Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Arvinas Inc
ARVN | US
8.00
USD-0.58
-6.76%
ARVN | US
About Arvinas Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
8.00
Open
8.44
High
8.60
Low
7.98
Arvinas Inc. a clinical-stage biotechnology company engages in the discovery development and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766 investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer which are in Phase 1/2 clinical trials; and ARV-471 an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc. Genentech Inc. F. Hoffman-La Roche Ltd. and Bayer AG. Arvinas Inc. was founded in 2013 and is based in New Haven Connecticut.
View LessARVN | US
Risk
48.2
Sharpe
0.11
Luna's Score
43/100
Recommendation
Sell
Luna says (ARVN | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
56.2%1 month
48.2%3 months
52.6%6 months
52.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
17.70
Price to book
3.09
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
-1.62
Ent. to rev.
6.75
PEG
-
Other Fundamentals
EBITDA
-366.20M
MarketCap
547.77M
MarketCap(USD)
547.77M
Div. yield
-
Op. margin
-63.40
Erngs. growth
-
Rev. growth
40.40
Ret. on equity
-60.80
Short ratio
24.36
Short perc.
15.83
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.36
Range1M
3.02
Range3M
6.53
Volumes: Market Activity
Rel. volume
0.89
Price X volume
6.67M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.62 | - | Cheaper |
| Ent. to Revenue | 6.75 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.09 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 52.61 | - | Lower Risk |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 547.77M | - | Emerging |
